The requirement for cell surface galactosyl residues during oxidative activation of normal and chronic lymphocytic leukemia lymphocytes.
D004247:DNA / Q000096:biosynthesis; D005692:Galactose Oxidase / Q000494:pharmacology*; D006801:Humans; D007945:Leukemia, Lymphoid / Q000097:blood*; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D009439:Neuraminidase / Q000494:pharmacology; D010504:Periodic Acid / Q000494:pharmacology*; D001616:beta-Galactosidase / Q000494:pharmacology
D010504:Periodic Acid; D004247:DNA; D005692:Galactose Oxidase; D009439:Neuraminidase; D001616:beta-Galactosidase